With over four decades of experience, CONCI has built a legacy of success stories, with countless individuals achieving significant weight loss and improved overall health under our care. The personalized approach and comprehensive strategies employed by CONCI help individuals achieve their weight loss goals and instill a sense of empowerment and confidence in their ability to lead healthier lifestyles.
One of the pillars of CONCI's success is its commitment to staying at the forefront of scientific research and advancements in obesity treatment. By leveraging the latest findings and innovations, CONCI can offer cutting-edge solutions that are both effective and sustainable for our patients.
The following includes some our research and publications:
Medical Weight Loss vs Losing Weight on Your Own
If you've struggled with weight loss on your own, you're not alone. Understanding the difference between medical weight loss and losing weight independently can help you make an informed decision about which approach is right for you. We're more than happy to talk to...
How Does Tirzepatide Work for Weight Loss?
What is Zepbound (Tirzepatide)? Tirzepatide (better known by the brand name Zepbound) is an FDA-approved dual-acting drug for weight loss and obstructive sleep apnea. What's the Difference Between Tirzepatide and Other Weight Loss Drugs? Mounjaro and Zepbound Contain...
GLP-1: The Hormone Transforming Obesity Medicine and Weight Loss
What is a GLP-1 Agonist? GLP-1 (glucagon-like peptide-1) drugs like semaglutide (you may know the brand names Ozempic and Wegovy) are GLP-1 receptor agonists. Glucagon-like peptide-1 is an incretin hormone naturally released in the human body in response to food and...
Combining Meal Replacement Products with Ozempic, Wegovy (Semaglutide), and other GLP-1 Weight Loss Drugs
Obesity has been identified as a chronic disease since the World Health Organization (WHO) declared so in 1997. This was an instrumental milestone in treating and accepting obesity as a chronic condition. Since then, the research has demonstrated the leading cause of...
Ongoing Research: Effects of VLCD and Drug Treatment for Obesity. (Protocol I. Protocol F. CONCI)
Five-year Maintenance Results of an Obesity Drug Following a Very Low Calorie Diet (VLCD) Presented at Obesity Week, 2013
J Loper, R Lutes, T Broyles, R May, E Baltes.
Naltrexone SR/Bupropion SR Combination Therapy Reduces Total and Visceral Adiposity in Overweight and Obese Subjects in the COR-1 Study. American Diabetes Association, 2011.
Smith S, T Church, J Goohas, C Griffin, W Harper, D Krieger, J Loper, Smudahar, C Woodrugg, M Guittalauria, E Henry, D Kim, E Dunayevich.
Naltrexone SR/Bupropion SR Therapy Reduced Body Weight and HgbA1C in Overweight/Obese Women with Type 2 Diabetes. American Diabetes Association, 2011.
P Hollander, J Loper, L Mignon, C Burns, R Harris-Collzao, D Kim.
Drug Treatment following a VLCD (Very Low Energy Diet). Obesity, Research Journal, 2010
Loper J, RA Lutes, JT Broyles, EJ Baltes, RK May.
Clinical Experience in a Comprehensive Weight-Management Center in the Management of Eating Disorders and Obesity, Humana Press, 2005
J Loper, RA Lutes, Edited by DJ Goldstein.